UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

MEK inhibition reprograms CD8 + T lymphocytes into memory stem cells with potent antitumor effects

Nature immunology, 2021-01, Vol.22 (1), p.53-66

2021

Volltextzugriff (PDF)

Age-induced changes in anti-tumor immunity alter the tumor immune infiltrate and impact response to immuno-oncology treatments

Frontiers in immunology, 2023-10, Vol.14, p.1258291-1258291

2023

Volltextzugriff (PDF)

Development trends for monoclonal antibody cancer therapeutics

Nature reviews. Drug discovery, 2007-05, Vol.6 (5), p.349-356

2007

Volltextzugriff (PDF)

Comprehensive Intrametastatic Immune Quantification and Major Impact of Immunoscore on Survival

JNCI : Journal of the National Cancer Institute, 2018-01, Vol.110 (1), p.97-108

2018

Volltextzugriff (PDF)

The tumor microenvironment and Immunoscore are critical determinants of dissemination to distant metastasis

Science translational medicine, 2016-02, Vol.8 (327), p.327ra26

2016

Volltextzugriff (PDF)

Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery

Cancer immunology research, 2017-01, Vol.5 (1), p.29-41

2017

Volltextzugriff (PDF)

Targeting DNA damage response components induces enhanced STING-dependent type-I IFN response in ATM deficient cancer cells and drives dendritic cell activation

Oncoimmunology, 2022-12, Vol.11 (1), p.2117321-2117321

2022

Volltextzugriff (PDF)

PARP inhibition is a modulator of anti-tumor immune response in BRCA-deficient tumors

Oncoimmunology, 2022-12, Vol.11 (1), p.2083755-2083755

2022

Volltextzugriff (PDF)

Dissecting the Role of BET Bromodomain Proteins BRD2 and BRD4 in Human NK Cell Function

Frontiers in immunology, 2021-02, Vol.12, p.626255-626255

2021

Volltextzugriff (PDF)

A cell-engineered system to assess tumor cell sensitivity to CD8+ T cell-mediated cytotoxicity

Oncoimmunology, 2019-08, Vol.8 (8), p.1-10

2019

Volltextzugriff (PDF)

Program Death-1 Engagement Upon TCR Activation Has Distinct Effects on Costimulation and Cytokine-Driven Proliferation: Attenuation of ICOS, IL-4, and IL-21, But Not CD28, IL-7, and IL-15 Responses

The Journal of immunology (1950), 2003-01, Vol.170 (2), p.711-718

2003

Volltextzugriff (PDF)

877 Intermittent dosing of the ataxia telangiectasia and Rad3-related (ATR) inhibitor ceralasertib promotes antitumor immunity by remodelling the tumor immune microenvironment in pre-clinical models

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 1), p.A977-A977

2023

Volltextzugriff (PDF)

In vitro potency, pharmacokinetic profiles and pharmacological activity of optimized anti-IL-21R antibodies in a mouse model of lupus

mAbs, 2010-05, Vol.2 (3), p.335-346

2010

Volltextzugriff (PDF)

Nuclear factor of activated T cells contains Fos and Jun

Nature (London), 1992-04, Vol.356 (6372), p.801-804

1992

Volltextzugriff (PDF)

MHC class I chain-related protein A and B (MICA and MICB) are predominantly expressed intracellularly in tumour and normal tissue

British journal of cancer, 2017-04, Vol.116 (9), p.1208-1217

2017

Volltextzugriff (PDF)

Discovery of Proteolysis-Targeting Chimera Molecules that Selectively Degrade the IRAK3 Pseudokinase

Journal of medicinal chemistry, 2020-09, Vol.63 (18), p.10460-10473

2020

Volltextzugriff (PDF)

Inhibition of DNA-PK with AZD7648 Sensitizes Tumor Cells to Radiotherapy and Induces Type I IFN-Dependent Durable Tumor Control

Clinical cancer research, 2021-08, Vol.27 (15), p.4353-4366

2021

Volltextzugriff (PDF)

Functional network pipeline reveals genetic determinants associated with in situ lymphocyte proliferation and survival of cancer patients

Science translational medicine, 2014-03, Vol.6 (228), p.228ra37

2014

Volltextzugriff (PDF)

Abstract 4987: Age-induced changes in anti-tumor immunity alter the tumor immune infiltrate and reduce response to immuno-oncology treatments

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.4987-4987

2019

Volltextzugriff (PDF)

Abstract 967: Anti-tumor and immune effects of olaparib +/- anti-PD-L1 in preclinical BRCA1mut tumor models

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.967-967

2020

Volltextzugriff (PDF)

ATM Regulates Differentiation of Myofibroblastic Cancer-Associated Fibroblasts and Can Be Targeted to Overcome Immunotherapy Resistance

Cancer research (Chicago, Ill.), 2022-12, Vol.82 (24), p.4571-4585

2022

Volltextzugriff (PDF)

Discovery and characterisation of quinazolines and 8-Azaquinazolines as NLRP3 agonists with oral bioavailability in mice

Bioorganic & medicinal chemistry letters, 2023-11, Vol.96, p.129518-129518, Article 129518

2023

Volltextzugriff (PDF)

Discovery of PROTAC molecules that selectively degrade the IRAK3 pseudokinase

Journal of medicinal chemistry, 2020, Vol.63 (18), p.10460

2020

Volltextzugriff (PDF)

1 – 25 von 40

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(38)
Mit Volltextzugriff
(34)

Publikationsform

Artikel
(39)
Dissertationen
(1)

Sprache

Englisch
(40)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

MEK inhibition reprograms CD8 + T lymphocytes into memory stem cells with potent antitumor effects

Age-induced changes in anti-tumor immunity alter the tumor immune infiltrate and impact response to immuno-oncology treatments

Development trends for monoclonal antibody cancer therapeutics

Comprehensive Intrametastatic Immune Quantification and Major Impact of Immunoscore on Survival

The Link between the Multiverse of Immune Microenvironments in Metastases and the Survival of Colorectal Cancer Patients

The tumor microenvironment and Immunoscore are critical determinants of dissemination to distant metastasis

Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery

Targeting DNA damage response components induces enhanced STING-dependent type-I IFN response in ATM deficient cancer cells and drives dendritic cell activation

PARP inhibition is a modulator of anti-tumor immune response in BRCA-deficient tumors

Dissecting the Role of BET Bromodomain Proteins BRD2 and BRD4 in Human NK Cell Function

A cell-engineered system to assess tumor cell sensitivity to CD8+ T cell-mediated cytotoxicity

Program Death-1 Engagement Upon TCR Activation Has Distinct Effects on Costimulation and Cytokine-Driven Proliferation: Attenuation of ICOS, IL-4, and IL-21, But Not CD28, IL-7, and IL-15 Responses

877 Intermittent dosing of the ataxia telangiectasia and Rad3-related (ATR) inhibitor ceralasertib promotes antitumor immunity by remodelling the tumor immune microenvironment in pre-clinical models

In vitro potency, pharmacokinetic profiles and pharmacological activity of optimized anti-IL-21R antibodies in a mouse model of lupus

Nuclear factor of activated T cells contains Fos and Jun

Integrative Analyses of Colorectal Cancer Show Immunoscore Is a Stronger Predictor of Patient Survival Than Microsatellite Instability

MHC class I chain-related protein A and B (MICA and MICB) are predominantly expressed intracellularly in tumour and normal tissue

Discovery of Proteolysis-Targeting Chimera Molecules that Selectively Degrade the IRAK3 Pseudokinase

Inhibition of DNA-PK with AZD7648 Sensitizes Tumor Cells to Radiotherapy and Induces Type I IFN-Dependent Durable Tumor Control

Functional network pipeline reveals genetic determinants associated with in situ lymphocyte proliferation and survival of cancer patients

Abstract 4987: Age-induced changes in anti-tumor immunity alter the tumor immune infiltrate and reduce response to immuno-oncology treatments

Abstract 967: Anti-tumor and immune effects of olaparib +/- anti-PD-L1 in preclinical BRCA1mut tumor models

ATM Regulates Differentiation of Myofibroblastic Cancer-Associated Fibroblasts and Can Be Targeted to Overcome Immunotherapy Resistance

Discovery and characterisation of quinazolines and 8-Azaquinazolines as NLRP3 agonists with oral bioavailability in mice

Discovery of PROTAC molecules that selectively degrade the IRAK3 pseudokinase

Suchergebnisse filtern